CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Vicapsys Life Sciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Vicapsys Life Sciences Inc
1735 Buford Highway, Ste. 215-113
Phone: (470) 514-4013p:470 514-4013 CUMMING, GA  30041  United States Ticker: VICPVICP
Business Summary
Vicapsys Life Sciences, Inc. develops and commercializes, on a worldwide basis, various intellectual property rights relating to a series of encapsulated products that incorporate proprietary derivatives of the chemokine CXCL12 for creating a zone of immunoprotection around cells, tissues, organs and devices for therapeutic purposes. VICAPSYN is the Company’s product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field. The lead product candidate embodiment in transplantation therapy to treat Type 1 Diabetes (T1D) is an encapsulated human islet cell cluster that is intended to restore normal glucose control when implanted into the peritoneal cavity of a patient. It also develops another product candidate line based on CXCL12 with the trade name of VYBRIN. The clinical applications of VYBRIN are being explored in several areas, including prevention of post-surgical adhesions in abdominal surgery and others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Executive Chairman of the Board FedericoPier 55 2/1/2022 5/1/2019
Chief Financial Officer JefferyWright 40 2/1/2020 2/1/2020
Director DorothyJordan 66
3 additional Officers and Directors records available in full report.

Business Names
Business Name
B&M Construction Co., Inc
B&M Construction of Arkansas, LLC
B&M Pump & Tank, Inc.
ViCapsys,Inc.
VICP
Willis Electric, L.L.C.

General Information
Number of Employees: 2 (As of 12/31/2022)
Outstanding Shares: 32,071,299 (As of 11/14/2023)
Shareholders: 300
Stock Exchange: OTC
Federal Tax Id: 621153426


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024